RT info:eu-repo/semantics/article
T1 Androgen Receptor Gene Polymorphisms and the Fat‐Bone Axis in Young Men and Women
A1 Ponce González, Jesús Gustavo
A1 Guadalupe Grau, Amelia
A1 Rodríguez González, Francisco Germán
A1 Dorado, Cecilia
A1 Olmedillas, Hugo
A1 Fuentes Nieto, Teresa
A1 Rodríguez García, Lorena
A1 Díaz Chico, Bonifacio Nicolás
A1 Calbet, José A. L.
AB Androgen receptor (AR) CAGn (polyglutamine) and GGNn(polyglycine) repeat polymorphisms determine part of the androgenic effect and may influence adiposity. The association of fat mass, and its regional distribution, with the AR CAGn and GGNn polymorphisms was studied in 319 and 78 physically active nonsmoker men and women (mean ± SD: 28.3 ± 7.6 and 24.8 ± 6.2 years old, respectively). The length of CAG and GGN repeats was determined by polymerase chain reaction and fragment analysis, and confirmed by DNA sequencing of selected samples. Men were grouped as CAG short (CAGS) if harboring repeat lengths ≤21, the rest as CAG long (CAGL). The corresponding cutoff CAG number for women was 22. GGN was considered short (GGNS) if GGN ≤23, the rest as GGN long (GGNL). No association between AR polymorphisms and adiposity or the hormonal variables was observed in men. Neither was there a difference in the studied variables between men harboring CAGL + GGNL,CAGS + GGNS,CAGS + GGNL, and CAGL + GGNS combinations. However, in women, GGNn was linearly related to the percentage of body fat (r = 0.30, P < .05), the percentage of fat in the trunk (r = 0.28, P < .05), serum leptin concentration (r = 0.40, P < .05), and serum osteocalcin concentration (r = 0.32, P < .05). In men, free testosterone was inversely associated with adiposity and serum leptin concentration, and positively with osteocalcin, even after accounting for differences in CAGn, GGNn, or both. In summary, this study shows that the AR repeat polymorphism has little influence on absolute and relative fat mass or its regional distribution in physically active men. In young women, GGN length is positively associated with adiposity, leptin, and osteocalcin.
SN 0196-3635
YR 2013
FD 2013-01
LK https://uvadoc.uva.es/handle/10324/72647
UL https://uvadoc.uva.es/handle/10324/72647
LA spa
NO Journal of Andrology, 2012, vol. 33, p. 644-650
NO Producción Científica
DS UVaDOC
RD 04-abr-2025